At the"9th SmartKarma Capital Market Annual Conference and Listed Companies Awards Ceremony,"KEENSEA Medical Technology(02225)was honored with the title of"Most Valuable Pharmaceutical and Medical Company."As a highly acclaimed enterprise within the industry,KEENSEA Medical Technology has garnered extensive recognition from investors for its remarkable technological innovation and outstanding market performance.

The "Most Valuable Pharmaceutical and Medical Company" award recognizes Hong Kong and U.S.-listed pharmaceutical and medical companies that have a healthy corporate governance structure, significant industry status, and robust core business operations, and are able to provide investors with continuous and stable value returns. KEENSEA Medical Technology's receipt of the "Most Valuable Pharmaceutical and Medical Company" award this time is not only an acknowledgment of the company's efforts over the past year but also an indication that it will continue to lead industry development and promote the application of more innovative achievements in the future.As a medical technology company specializing in the field of high-end endoscopy, KEENSEA Medical Technology has gradually become a well-known brand in the field of minimally invasive surgical solutions and related medical products and services, thanks to its strong R&D capabilities and innovation power.Looking back at this year, KEENSEA Medical Technology has achieved fruitful results in technological innovation and product breakthroughs.

Technological Innovation Breakthroughs and Widespread Market Recognition
KEENSEA Medical Technology, specializing in the field of high-end endoscopy, has established a strong reputation in minimally invasive surgical solutions and related medical products and services, thanks to its robust R&D capabilities and innovative power. Notably, the company's Endo Next series True 4K 3D 4MOS Ultra-High Definition Fluorescence Endoscopy System, launched in July 2023, integrates the "4K + 3D + fluorescence" triad technology and introduces the world's first AI voice control function, significantly enhancing operational convenience and application safety.On the technical front, KEENSEA Medical's 3D image generation device uses a software algorithm converter to add depth perception to digital 2D images. The resulting images are clearer than traditional arthroscopic images, with a broader field of view and improved visual depth of field. This represents a significant breakthrough in the domestic medical device sector. The system was also successfully selected for the 2023 Shanghai Innovative Medical Device Application Demonstration Project, validating its technological value. Moreover, it has obtained a Class II medical device license from the Shanghai Municipal Drug Administration and has multiple successful application cases.Building on its deep expertise in endoscopy technology, KEENSEA Medical has also expanded into the field of percutaneous endoscopic lumbar discectomy (PELD) and minimally invasive spinal surgery this year, aiming to diversify its product offerings and applications in the endoscopy field, enrich its product lines and application departments, and provide patients with higher-quality treatment solutions.In terms of technological reserves, KEENSEA Medical currently holds over 60 patents, more than 20 trademarks, and has over 30 ongoing research projects, demonstrating its strong capabilities in technological innovation and intellectual property protection. In the "Minimally Invasive 4.0 Era," KEENSEA Medical leads comprehensively in basic technologies, including three/four-chip, naked-eye 3D, 4K, 3D, and fluorescence. Amid the rapid development of AI, KEENSEA Medical is also actively advancing its R&D technology towards "Minimally Invasive 5.0." The company will focus on molecular probes, multi-spectrum, intelligent navigation, AI, AR enhancement, and infrared technologies in the future.Thanks to its outstanding R&D capabilities, KEENSEA Medical has received numerous honors and widespread market recognition. Specifically, in the 15th "China Best Medical Engineer Selection" in 2024, KEENSEA Medical's "4K Fluorescence Naked-Eye 3D Intelligent Navigation Endoscopy System" was selected as one of the "Top Ten Medical Equipment Upgrade Solutions in China." The company's endoscopy project also won the "Most Investment Value Award" at the 10th China Medical Industry Innovation Competition. Additionally, with its "4K Naked-Eye 3D Fluorescence Intelligent Navigation Endoscopy System" project, KEENSEA Medical made it to the "Top 10 Medical Device Innovation Potential Seed List" of the 2024 China Health Industry Awards.

Revenue Soars, Stock Price Rises Against the Trend by Nearly 2.5 Times
Technological Innovation Reflects in Financial,PerformanceIn terms of financial performance, KEENSEA Medical Technology has also delivered remarkable results. In the first half of this year, the company's revenue reached 25.937 million Singapore dollars, a significant year-on-year increase of 116.45%. This substantial growth reflects the strong market demand for its products and the competitiveness of its offerings.
The robust performance has also driven KEENSEA Medical's stock price upward. According to information from SmartKarma, while the Hang Seng Healthcare Index has been under pressure and has fallen by 15.27% year-to-date, KEENSEA Medical's stock price has defied the trend and surged nearly 2.5 times. This has generated substantial returns for investors.
Over the past year, KEENSEA Medical has garnered high recognition from both the capital market and the industry for its outstanding performance and technological innovation in the field of high-end endoscopy.
Looking Ahead Going forward, KEENSEA Medical will continue to focus on the endoscopy field, developing more innovative products to enhance medical standards and provide better treatment solutions for patients.